Moreover, we showed a significant association between early tumor stage and mutations in TAF1, LRP1B, SDHA, CBFB, BRIP1, and SMAD4. Chen et al. reported that LRP1B mutation was associated with better survival in NSCLC patients treated with immunotherapy53. This evidence concerns the gene SMAD4 and non-small cell lung carcinoma.